Search

The success of cancer chemotherapy has increased greatly the potential areas for its inclusion in clinical trials and therefore has made the experimental design considerations more complex in these trials. New drugs which are launched yet go through the three classic phases of clinical study beginning with clinical pharmacology (Phase I), efficacy screening (Phase 2) and role delineation (Phase 3). The Phase 2 and 3 trials now need to be considered within the overall therapeutic strategies which are required for each of the many diseases which are called cancer. Drugs consumed in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from increase exponentially. may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cytarabine is more effective in treating acute myeloid leukemia. The motive of this study is to assess the efficacious and eternal side effects of using combined tretinoin and arsenic trioxide in treating patients with newly detection of acute promyelocytic leukemia. Chemotherapy was identical, except for the addition of DTIC (300 mg/m2) for each course. A new drug may have required a lot of Phase 2 and 3 trials in a variety of tumors before it can be considered appropriately estimated. Essential aspects of valid clinical trials include an adequate protocol which details the study which is viable not for the current status but also for the future aspects. [ABSTRACT FROM AUTHOR]